IRVINE, Calif.--(BUSINESS WIRE)--
Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Alcobra, Ltd. (“Alcobra” or the “Company”) (Nasdaq: ADHD) concerning possible violations of federal securities laws
If you purchased shares of Alcobra and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
The investigation is intended to determine whether Alcobra and some of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Alcobra is a biopharmaceutical company that makes and markets oral drug candidates. On January 17, 2017, Alcobra disclosed that the Company's attention deficit hyperactivity disorder drug, Metadoxine Extended Release, could not reach its primary endpoint during a Phase 3 trial. When this information was revealed to the investing public, the value of Alcobra stock dropped, causing investors serious harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170131005944/en/
